'Real-life' experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors

European Journal of Haematology
Sophia DanhofStefan Knop

Abstract

Carfilzomib, the second-generation proteasome inhibitor, is still awaiting approval for the treatment of multiple myeloma in Europe. Results from clinical trials have demonstrated favorable efficacy in advanced disease but have opened an ongoing debate on cardiac complications related to carfilzomib treatment. 'Real-life' data are scarce. At our institution, 22 patients were registered within the European Carfilzomib Access Program for treatment with carfilzomib, dexamethasone, and a third combination partner depending on patient characteristics and prior treatment. Patients had received a median of six previous lines of therapy, and most were refractory to bortezomib (77%) and immunomodulatory drugs (95%). Overall response rate was 65% with a median progression-free survival of 6.0 months and a median duration of response of 6.8 months. Median overall survival was 14.9 months. Grade 3/4 adverse events (AEs) occurred in 50% of patients with 23% experiencing left ventricular failure. The risk of cardiac AEs was markedly increased after previous radiotherapy of the thoracic spine and concomitant administration of doxorubicin. Carfilzomib-based treatment is efficient in advanced multiple myeloma. In our 'real-life' patients, we fo...Continue Reading

References

Jul 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A C BravermanR T Lee
Dec 22, 1988·The New England Journal of Medicine·W McBrideJ T Willerson
Aug 1, 1973·Cancer·E A LefrakJ A Gottlieb
May 1, 1981·Archives of Internal Medicine·J S GottdienerJ Ziegler
Sep 1, 1999·Proceedings of the National Academy of Sciences of the United States of America·L MengC M Crews
Nov 24, 1999·The New England Journal of Medicine·S SinghalB Barlogie
Aug 3, 2004·Nature Reviews. Immunology·Thomas A Wynn
Jun 17, 2005·The New England Journal of Medicine·Paul G RichardsonUNKNOWN Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators
Jun 2, 2006·The Journal of Biological Chemistry·Qin Wei, Yong Xia
Dec 26, 2006·International Journal of Radiation Oncology, Biology, Physics·Susanne Schultz-Hector, Klaus-Rüdiger Trott
Jun 15, 2007·British Journal of Haematology·Orciuolo EnricoPetrini Mario
Nov 23, 2007·The New England Journal of Medicine·Meletios DimopoulosUNKNOWN Multiple Myeloma (010) Study Investigators
Aug 30, 2008·The New England Journal of Medicine·Jesús F San MiguelUNKNOWN VISTA Trial Investigators
Jun 4, 2010·The American Journal of Pathology·Dominika NowisJakub Golab
Sep 9, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Heinz LudwigNiklas Zojer
Feb 5, 2011·Blood·S Vincent RajkumarUNKNOWN International Myeloma Workshop Consensus Panel 1
Feb 26, 2011·International Journal of Cancer. Journal International Du Cancer·Jacques FerlayDonald Maxwell Parkin
Mar 25, 2011·Nature·Michael A ChapmanTodd R Golub
Apr 14, 2012·Blood·Jonathan J KeatsP Leif Bergsagel
May 2, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hervé Avet-LoiseauPhilippe Moreau
Jul 5, 2012·Current Cardiology Reviews·Maria Volkova, Raymond Russell
Mar 15, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J FerlayF Bray
Apr 26, 2013·European Journal of Heart Failure·Joerg HerrmannAmir Lerman
Jun 19, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Thomas M HerndonRichard Pazdur
Jun 21, 2013·Fundamental & Clinical Pharmacology·Benjamin HontonAtul Pathak
Aug 2, 2014·Haematologica·Jacob P LaubachPaul G Richardson
Sep 13, 2014·Hematology/oncology Clinics of North America·Kenneth C Anderson
Sep 17, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kyriakos P PapadopoulosAshraf Badros
Dec 3, 2014·Hematology/oncology Clinics of North America·Sarah A HolsteinPhilip L McCarthy
Dec 9, 2014·The New England Journal of Medicine·A Keith StewartUNKNOWN ASPIRE Investigators
Dec 30, 2014·Lancet·Christoph RölligMartin Bornhäuser
Mar 6, 2015·Frontiers in Oncology·Neil K TaunkSharad Goyal
Apr 4, 2015·Blood·Philippe MoreauThierry Facon
Jul 15, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Klaus MurbraechCecilie E Kiserud

❮ Previous
Next ❯

Citations

Feb 20, 2016·European Journal of Haematology·Eli MuchtarHila Magen
May 27, 2016·Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology·Carol Chen-ScarabelliTiziano M Scarabelli
Nov 30, 2016·Expert Review of Anticancer Therapy·Marco SalviniAlessandra Larocca
Jan 25, 2017·Expert Review of Hematology·Annamaria BrioliMarie Von Lilienfeld-Toal
Mar 10, 2017·Blood·Michel Delforge, Heinz Ludwig
Apr 12, 2017·Antioxidants & Redox Signaling·Carlo Gabriele TocchettiGiuseppe Mercuro
Mar 21, 2017·Medicina intensiva·R Rodríguez-GarcíaD Escudero
Feb 16, 2018·Clinical Pharmacology and Therapeutics·Neeraj GuptaKarthik Venkatakrishnan
Mar 7, 2018·Current Treatment Options in Cardiovascular Medicine·Dae Hyun Lee, Michael G Fradley
Nov 15, 2017·Expert Opinion on Pharmacotherapy·Dimitrios C ZiogasMeletios A Dimopoulos
Dec 3, 2017·Cancer Metastasis Reviews·Sara GandolfiPaul G Richardson
Nov 23, 2017·Expert Review of Cardiovascular Therapy·Pankaj MathurJawahar L Mehta
Sep 16, 2017·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Gee Youn KimFrank Cirrone
Jul 31, 2018·Future Oncology·Susanne Strifler, Stefan Knop
Oct 20, 2018·Expert Review of Hematology·Agne PanerEdward N Libby
Sep 10, 2016·F1000Research·Binod DhakalParameswaran Hari
Dec 6, 2018·Cardiovascular & Hematological Disorders Drug Targets·W SerraA Chetta
Nov 20, 2019·Cancers·Su Min Nam, Young Joo Jeon
Oct 28, 2017·Cardiology in Review·Daniel C Cole, William H Frishman
Jan 4, 2018·Blood Advances·Meletios A DimopoulosEfstathios Kastritis
Jun 21, 2018·Current Treatment Options in Cardiovascular Medicine·Isaac B Rhea, Guilherme H Oliveira
May 15, 2020·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Tienush RassafUNKNOWN Committee for Clinical Cardiovascular Medicine of the German Cardiac Society
Jun 10, 2020·Current Oncology Reports·Perry WuEric H Yang
Mar 28, 2018·High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension·Andrea IannacconeA Milan
Feb 6, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Robert Z Orlowski, Sagar Lonial
Dec 4, 2020·The Lancet Oncology·Shaji K KumarS Vincent Rajkumar
May 14, 2021·Circulation Research·Virginia S HahnBonnie Ky
Oct 15, 2020·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Shahaf TulerConstantin A Dasanu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiotoxicity

Cardiotoxicity refers to the muscle damage or dysfunction of heart electrophysiology caused by drug intake or due to disease complications. It is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. Here is the latest research.